KURE is trading at $19.50, up 3.77% on September 30 amid broad China biotech and healthcare ETF gains; no KURE-specific announcement surfaced. - In Hong Kong, ChinaAMC Hang Seng Biotech rose 4.01%; several biotech-focused funds gained over 3.2%, consistent with KURE’s China healthcare exposure but not confirming a cause. - Novo Nordisk’s licensing deal with KURE holding Jiangsu Hengrui Pharmaceuticals is worth up to $2.6 billion. Reports said Hengrui shares rose, but reporting does not establish the deal as the cause of KURE’s intraday gain.